

# Epstein-Barr Virus Infection Precedes Some Stomach Cancers; The CBCD Reviews the Medical Evidence

*A study noted that there is “evidence of virus infection in premalignant lesions, such as dysplastic epithelial cells.” (1)*

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, May 23, 2016 /EINPresswire.com/ --

“Infected with the Epstein Barr Virus (EBV)? The CBCD recommends taking [Novirin](#) or [Gene-Eden-VIR.](#)” - Greg Bennett, CBCD

A study noted that the Epstein-Barr Virus (EBV) is found in gastric cancer (stomach cancer) tumors. As Dr. Jacome and colleagues wrote, “EBV-positive GC is defined by the presence of virus in tumor cells.” (1) While some may assume an association between EBV and stomach cancer since the virus is found in tumor cells, there is a stronger link. It is now assumed by scientists that the virus may be involved in the pathogenesis (beginnings) of gastric cancer due to its presence in pre-cancerous lesions. (1) Dr. Jacome is from the Hospital Mater Dei at Belo Horizonte in Minas Gerais, Brazil.

New research also suggests that that the latent EBV can cause cellular changes that become cancer in those with a healthy immune system. Dr. Eminger and colleagues wrote that “over the past few decades, cumulative research has revealed that latent EBV infection may be implicated in the pathogenesis of a heterogeneous group of lymphoproliferative disorders and

malignancies occurring in both immunocompetent and immunocompromised hosts.” (2) Dr. Eminger is from the Geisinger Medical Center in Danville, Pennsylvania.



studies, the rate of infection ranges from 22.2% to 41.2%. (3) These studies are very clear. Latent EBV is associated with cancer. "Most EBV associated cancers contain viral DNA that exists predominantly as a latent infection in which only a limited set of viral genes are expressed. These latency associated genes are implicated in host-cell proliferation and survival, and latent EBV can directly promote tumor progression." (3)

The Center for the Biology of Chronic Disease (CBCD) recommends that in light of the medical evidence, individuals concerned about infection with the latent EBV take Gene-Eden-VIR or Novirin. The formula of these natural, antiviral supplements was designed to help the immune system target the latent form of the Epstein-Barr Virus.

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin formula is effective against the herpes family of viruses. The Epstein Barr Virus (EBV) is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the EBV ... reported a safe decrease in their symptoms following treatment with (the formula of Novirin)." (4) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (4)

Gene-Eden-VIR and Novirin can be ordered online on their respective websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Some doctors argue that latent viruses are inactive, that is, they show no transcription (production of proteins) and no shedding. Since the virus is inactive it is harmless. In contrast, Dr. Tikhmyanova wrote that "Epstein-Barr Virus (EBV) persists as a latent infection in many lymphoid and epithelial malignancies, including Burkitt's lymphomas, nasopharyngeal carcinomas, and gastric carcinomas. Current chemotherapeutic treatments of EBV-positive cancers include broad-spectrum cytotoxic drugs that ignore the EBV-positive status of tumors." (5) The evidence is building that latent viruses are active, although on a reduced scale, and are still dangerous.

The CDC notes that "Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives." (5) The Center for the Biology of Chronic Disease (CBCD) recommends that in light of the medical evidence, infected individuals take Novirin or Gene-Eden-VIR. The formula of these natural, antiviral supplements was designed to help the immune system target the latent EBV.

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us Twitter on here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Jacome, A. A., E. M. Lima, A. I. Kazzi, E. F. Chavez, D. C. Mendonca, M. M. Maciel, and J. S. Santos. "Epstein-Barr Virus-positive Gastric Cancer: A Distinct Molecular Subtype of the Disease?" *Revista Da Sociedade Brasileira De Medicina Tropical*(April 2016). Pubmed. Web. 22 May 2016.

(2) Eminger LA1, Hall LD2, Hesterman KS3, Heymann WR4. "Epstein-Barr virus: Dermatologic associations and implications: Part II. Associated lymphoproliferative disorders and solid tumors." *J Am Acad Dermatol*. 2015 Jan;72(1):21-34.<http://www.ncbi.nlm.nih.gov/pubmed/25497918>

(3) Tikhmyanova N1, Schultz DC, Lee T, Salvino JM, Lieberman PM. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus. *ACS Chem Biol*. 2014 Mar 21;9(3):785-95.  
<http://www.ncbi.nlm.nih.gov/pubmed/24028149>

(4) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.  
<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

(5) Tikhmyanova N1, Schultz DC, Lee T, Salvino JM, Lieberman PM. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus. *ACS Chem Biol*. 2014 Mar 21;9(3):785-95.  
<http://www.ncbi.nlm.nih.gov/pubmed/24028149>

Greg Bennett  
CBCD  
585-250-9999  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.



